Literature DB >> 2585009

Behavior of the exposure odds ratio in a case-control study when the hazard function is not constant over time.

H A Guess1.   

Abstract

In case-control studies of adverse drug effects there is rarely much evidence to support the assumption that the hazard function among users is constant during therapy. Nonetheless, this assumption is often implicitly made. We will use both clinical reasoning and a simple model to show how non-constancy of the hazard function affects odds ratio interpretation. When the hazard function is non-constant and there is more than one temporal pattern of drug usage, the odds ratio will estimate a weighted mean of incidence ratios with weights dependent on the corresponding fractions of person-time. If the duration-specific incidence ratios differ widely, the odds ratio will depend not only on the drug but also on its usage pattern in the study population. This may explain some of the large regional odds ratio variation for dipyrone-related agranulocytosis in the International Agranulocytosis and Aplastic Anemia Study (JAMA 1986; 256: 1749-1757.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2585009     DOI: 10.1016/0895-4356(89)90116-9

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  13 in total

Review 1.  Design issues for drug epidemiology.

Authors:  A D McMahon; T M MacDonald
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

2.  Counterpoint: the treatment decision design.

Authors:  M Alan Brookhart
Journal:  Am J Epidemiol       Date:  2015-10-26       Impact factor: 4.897

3.  Statistical methods in pharmacoepidemiology. Principles in managing error.

Authors:  S Suissa
Journal:  Drug Saf       Date:  1991 Sep-Oct       Impact factor: 5.606

Review 4.  A pathway to improved prospective observational post-authorization safety studies.

Authors:  Victor A Kiri
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

Review 5.  Pharmacoepidemiologic Methods for Studying the Health Effects of Drug-Drug Interactions.

Authors:  S Hennessy; C E Leonard; J J Gagne; J H Flory; X Han; C M Brensinger; W B Bilker
Journal:  Clin Pharmacol Ther       Date:  2015-11-23       Impact factor: 6.875

6.  Methodological considerations when analysing and interpreting real-world data.

Authors:  Til Stürmer; Tiansheng Wang; Yvonne M Golightly; Alex Keil; Jennifer L Lund; Michele Jonsson Funk
Journal:  Rheumatology (Oxford)       Date:  2020-01-01       Impact factor: 7.580

7.  Clustering of venous thrombosis events at the start of tamoxifen therapy in breast cancer: a population-based experience.

Authors:  Adedayo A Onitilo; Suhail A R Doi; Jessica M Engel; Ingrid Glurich; John Johnson; Richard Berg
Journal:  Thromb Res       Date:  2011-12-07       Impact factor: 3.944

8.  The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application.

Authors:  Jennifer L Lund; David B Richardson; Til Stürmer
Journal:  Curr Epidemiol Rep       Date:  2015-09-30

9.  Use of Prescription Drug Samples in the USA: A Descriptive Study with Considerations for Pharmacoepidemiology.

Authors:  Christian Hampp; Patty Greene; Simone P Pinheiro
Journal:  Drug Saf       Date:  2016-03       Impact factor: 5.606

10. 

Authors:  Sinéad M Langan; Sigrún A J Schmidt; Kevin Wing; Vera Ehrenstein; Stuart G Nicholls; Kristian B Filion; Olaf Klungel; Irene Petersen; Henrik T Sørensen; William G Dixon; Astrid Guttmann; Katie Harron; Lars G Hemkens; David Moher; Sebastian Schneeweiss; Liam Smeeth; Miriam Sturkenboom; Erik von Elm; Shirley V Wang; Eric I Benchimol
Journal:  CMAJ       Date:  2019-06-24       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.